Amyloidosis Clinical Market to Reach USD 8.3 Billion by 2030

The Global Amyloidosis Clinical Market is entering a significant growth phase driven by rapid adoption of targeted therapies, increased diagnostic capabilities, and expanding clinical research focused on subtypes like AL, ATTR, AA, and hereditary amyloidosis. According to Exactitude Consultancy, the market is projected to grow from USD 4.8 billion in 2023 to USD 8.3 billion by 2030, reflecting a CAGR of 7.9%.

Amyloidosis is a complex and often underdiagnosed condition involving abnormal protein aggregation in organs such as the heart, kidneys, liver, and nervous system. Early detection and precise classification are now achievable due to advancements in molecular diagnostics and imaging.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73634

Key Takeaways
• Market Size 2023: USD 4.8 billion
• Market Size 2030: USD 8.3 billion
• CAGR (2024-2030): 7.9%
• Largest Segment: AL Amyloidosis diagnostics & therapeutics
• Fastest-Growing Area: ATTR-targeted drugs & RNA-based therapies

Market Story
Amyloidosis treatment has evolved dramatically in recent years. Improved diagnostic tools-including mass spectrometry, cardiac MRI, next-generation sequencing, and immunohistochemistry-allow earlier and more accurate identification of amyloid deposits.

Key drivers reshaping the market include:
• Breakthrough ATTR therapies (tafamidis, patisiran, inotersen)
• Expanded use of autologous stem cell transplant (ASCT) for AL amyloidosis
• RNA-targeted therapeutics improving clinical outcomes
• Increased cardiac imaging for ATTR cardiomyopathy
• Growing genomics-based screening for hereditary amyloidosis
• Clinical trials targeting fibril degradation & stabilization
Demand is rising for multidisciplinary clinical management across cardiology, hematology, nephrology, and neurology.
Market Segments
By Disease Type
• AL (Light Chain) Amyloidosis - Largest Segment
• ATTR Amyloidosis (Hereditary & Wild-Type) - Fastest Growing
• AA Amyloidosis
• Dialysis-Related Amyloidosis
• Other Rare Variants
ATTR cardiomyopathy is increasing rapidly due to aging populations and improved detection.

By Treatment Type
• Chemotherapy & Immunomodulatory Drugs (For AL)
- Bortezomib
- Daratumumab
- Cyclophosphamide
• Targeted ATTR Therapies (Largest Growth Segment)
- Tafamidis
- Patisiran (RNAi therapy)
- Inotersen (antisense oligonucleotide)
- Vutrisiran
• Supportive Care Therapies
- Heart failure management
- Kidney & liver support
- Neuropathy treatment
• Stem Cell Transplantation (ASCT)
• Emerging Therapy Pipeline
- Fibril-degrading agents
- TTR stabilizers
- Gene therapy candidates
RNA-based therapeutics show strong commercial traction.

By Diagnostic Method
• Mass Spectrometry (Gold Standard for Typing)
• Cardiac MRI & Echocardiography
• Immunohistochemistry (IHC)
• Bone Scintigraphy (DPD, PYP Scans for ATTR)
• Genetic Testing (Fastest Growing Diagnostic Segment)
• Biomarker Testing (NT-proBNP, Troponins)
Bone scintigraphy has revolutionized non-biopsy diagnosis of ATTR cardiomyopathy.

By End User
• Hospitals & Multispecialty Centers (Largest End User)
• Cardiology & Hematology Clinics
• Diagnostic Laboratories
• Academic Research Institutions
• Home Healthcare Providers
• Pharmaceutical & Biotech Research Centers
Growing collaboration between cardiologists and hematologists supports market expansion.

Explore Full Report here: https://exactitudeconsultancy.com/reports/73634/amyloidosis-clinical-market

Recent Industry Developments
• 2024 - Pfizer expanded global rollout of tafamidis (Vyndamax®) for ATTR cardiomyopathy.
• 2023 - Alnylam Pharmaceuticals advanced its RNAi therapy patisiran for both neuropathy and cardiomyopathy indications.
• 2023 - Ionis Pharmaceuticals progressed clinical trials for next-gen antisense therapies targeting TTR.
• 2023 - Prothena reported strong pipeline progress with its anti-amyloid monoclonal antibody programs.
• 2023 - Mayo Clinic & leading centers enhanced mass spectrometry adoption for precise amyloid typing.

Expert Quote
"Advancements in RNA-based therapies, improved diagnostics, and early detection programs are transforming amyloidosis care-offering patients better survival outcomes and faster, accurate disease classification."
- Irfan Tamboli, Business Development Executive, Exactitude Consultancy

Key Market Drivers
1. Rising Global Awareness & Early Diagnosis
Improved cardiac and molecular testing is reducing diagnostic delays.
2. Breakthrough ATTR Therapies
Novel TTR stabilizers and RNAi drugs deliver improved outcomes for cardiomyopathy and neuropathy.
3. Growth in AL Amyloidosis Treatment Options
Modern chemotherapy regimens and monoclonal antibodies expand therapeutic choices.
4. Adoption of Advanced Imaging Technologies
Cardiac MRI and bone scans enhance detection accuracy.
5. Expanding Clinical Research & Pipeline Programs
Biotech investments drive innovation across ATTR and AL amyloidosis.

Forecast Outlook (2024-2030)
Future developments will include:
• Gene therapy targeting root-cause protein misfolding
• New monoclonal antibodies for fibril clearance
• AI-driven diagnostics and imaging tools
• Growth in remote monitoring for cardiac amyloidosis
• Earlier screening for high-risk groups, including older adults
By 2030, amyloidosis care will be far more precision-driven, minimally invasive, and supported by advanced therapeutics.

Regional Insights
North America
Largest market due to strong clinical diagnostic infrastructure, therapeutic availability, and research activity.
Europe
Well-established amyloidosis treatment centers and increasing ATTR awareness programs.
Asia-Pacific (Fastest Growing Region)
Rising adoption of diagnostic imaging and increased detection of hereditary amyloidosis in Japan, China, and South Korea.
Latin America & Middle East
Gradual growth driven by improved diagnostic capacity and specialist clinics.

Conclusion
The Amyloidosis Clinical Market is expanding steadily as early diagnostic tools, targeted drug therapies, RNA-based treatments, and multidisciplinary care strategies significantly improve patient outcomes. With rapid innovation and growing awareness, the market is entering a new era of precision amyloidosis management.

This report is also available in the following languages : Japanese (アミロイドーシス臨床市場), Korean (아밀로이드증 임상 시장), Chinese (淀粉样变性临床市场), French (Marché clinique de l'amylose), German (Klinischer Markt für Amyloidose), and Italian (Mercato clinico dell'amiloidosi), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73634

Related Reports

Idiopathic Pulmonary Fibrosis Clinical Market
https://exactitudeconsultancy.com/reports/73630/idiopathic-pulmonary-fibrosis-clinical-market

Plaque Psoriasis (Psoriasis Vulgaris) Clinical Market
https://exactitudeconsultancy.com/reports/73631/plaque-psoriasis-psoriasis-vulgaris-clinical-market

Gaucher Disease Clinical Market
https://exactitudeconsultancy.com/reports/73632/gaucher-disease-clinical-market

Inflammatory Bowel Disease Clinical Market
https://exactitudeconsultancy.com/reports/73633/inflammatory-bowel-disease-clinical-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.